ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
16 announcements with these filters
Zensar Technologies allotted 31,440 equity shares to employees on exercise of ESOPs. Paid-up share capital rose to ₹45.55 crore across 22.78 crore shares.
Zensar Technologies Ltd disclosed an employee's market sale of 20,000 equity shares on 02-11-2026, reducing holding from 41,977 to 21,977 shares. Value stated is Rs.1.09 Crore.
Zensar Technologies disclosed equity share sales by two employees totaling Rs. 0.75 Crore. Nimesh Khemka and Rajiv Mundhra executed market sales on November 2, 2026.
Zensar delivered secular revenue growth and margin expansion despite macro headwinds, pivotting heavily toward AI-native service delivery.
Zensar Technologies reported 4.1% sequential constant currency revenue growth to $166.2M for Q2FY27, with EBITDA margin at 15.8%. The release is a press release accompanying the quarterly results presentation.
Zensar's board approved merging its wholly owned subsidiary M3bi India into the parent. No consideration or share issuance is involved, and NCLT sanction is pending.
Zensar Technologies Ltd reported revenue from operations of ₹1,585 Cr (+11.5% YoY) and net profit of ₹190.2 Cr (+4.4% YoY) for Q2 FY27.
Zensar Technologies has been assigned an overall ESG rating of 76 in the 'Leader' category by NSE Sustainability Ratings and Analytics Limited.
Zensar Technologies submitted its Regulation 74(5) compliance certificate for the quarter ended September 30, 2026, confirming RTA dematerialization records were furnished to depositories.
Zensar Technologies allotted 162,619 equity shares upon the exercise of ESOPs by employees. This allotment increases the company's issued and subscribed share capital.
Zensar Technologies has scheduled a board meeting for October 28, 2026, to approve the unaudited standalone and consolidated financial results for the quarter ending September 30, 2026.
ICRA Limited has reaffirmed the credit rating of Zensar Technologies for its long-term and short-term fund/non-fund based bank facilities, totaling ₹191 Crore.
Designated person Vijayasimha Alilughatta acquired 8,983 shares of Zensar Technologies through an ESOP exercise. The transaction is valued at ₹0.43 Crore.
Zensar Technologies has allotted 25,691 equity shares to employees following the exercise of their vested ESOPs.
Zensar Technologies Ltd has filed its quarterly shareholding pattern for the period ended December 31, 2025, in compliance with regulatory requirements.
Zensar Technologies announced the completed merger of its US subsidiaries M3BI LLC and Bridgeview Life Sciences LLC into Zensar Technologies Inc. The mergers become effective September 1, 2026.